1.Tsuang, MT, Faraone, SV. The Genetics of Mood Disorders. Baltimore, Md: Johns Hopkins University Press; 1990.
2.Prathikanti, S, McMahon, FJ. Genome scans for susceptibility genes in bipolar affective disorder. Ann Med. 2001;33:257–262.
3.Craddock, N, Jones, I. Molecular genetics of bipolar disorder. Br J Psychiatry. 2001;178(suppl):128–133.
4.Kelsoe, JR. Recent progress in the search for genes for bipolar disorder. Current Psychiatry Reports. 1999;1:135–140.
5.Berrettini, WH. Susceptibility loci for bipolar disorder: overlap with inherited vulnerability to schizophrenia. Biol Psychiatry. 2000;47:245–251.
6.Terwilliger, JD, Shannon, WD, Lathrop, GM, et al.True and false positive peaks in genomewide scans: applications of length-biased sampling to linkage mapping. Am J Hum Genet. 1997;61:430–438.
7.Venter, JC, Adams, MD, Myers, EW, et al.The sequence of the human genome. Science. 2001;291:1304–1351.
8.Lander, ES, Linton, LM, Birren, B, et al.Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.
9.Sibille, E, Hen, R. Combining genetic and genomic approaches to study mood disorders. Eur Neuropsychopharmacol. 2001;11:413–421.
10.Rossant, J, McKerlie, C. Mouse-based phenogenomics for modeling human disease. Trends Mol Med. 2001;7:502–507.
11.Gainetdinov, RR, Jones, SR, Caron, MG. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol Psychiatry. 1999;46:303–311.
12.Ralph, RJ, Paulus, MP, Furmagalli, F, Caron, MG, Geyer, MA. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci. 2001;21:305–313.
13.Decker, S, Grider, G, Cobb, M, et al.Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:455–462.
14.Petty, F, Sherman, AD. A pharmacologically pertinent animal model of mania. J Affect Disord. 1981;3:381–387.
15.Fibiger, HC. The dopamine hypothesis of schizophrenia and mood disorders: contradictions and speculations. In: The Mesolimbic Dopamine System: from Motivation to Action. Chichester, England: John Wiley and Sons; 1991:615–637.
16.Jacobs, D, Silverstone, T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med. 1986;16:323–329.
17.Angrist, B. Amphetamine psychosis: clinical variations of the syndrome. In: Amphetamine and Its Analogues. San Diego, Calif: Academic Press; 1994:387–414.
18.Smith, RE, Haroutunian, V, Davis, KL, Meador-Woodruff, JH. Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport. 2001;12:2885–2887.
19.Meador-Woodruff, JH, Davis, KL, Haroutunian, V. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacol. 2001;24:545–552.
20.Mimics, K, Middleton, FA, Marquez, A, Lewis, DA, Levitt, P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53–67.
21.Mimics, K, Middleton, FA, Stanwood, GD, Lewis, DA, Levitt, P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry. 2001;6:293–301.
22.Mimics, K, Middleton, FA, Lewis, DA, Levitt, P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 2001;24:479–486.
23.Hakak, Y, Walker, JR, Li, C, et al.Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001;98:4746–4751.
24.Lewohl, JM, Dodd, PR, Mayfield, RD, Harris, RA. Application of DNA microarrays to study human alcoholism. J Biomed Sci. 2001;8:28–36.
25.Lewohl, JM, Wang, L, Miles, MF, et al.Gene expression in human alcoholism: microarray analysis of frontal cortex. Alcohol Clin Exp Res. 2000;24:1873–1882.
26.Niculescu, AB 3rd, Segal, DS, Kuczenski, R, et al.Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genomics. 2000;4:83–91.
27.Yoon, IS, Li, PP, Siu, KP, et al.Altered IMPA2 gene expression and calcium homeostasis in bipolar disorder. Mol Psychiatry. 2001;6:678–683.
28.Yoon, IS, Li, PP, Siu, KP, et al.Altered TRPC7 gene expression in bipolar-I disorder. Biol Psychiatry. 2001;50:620–626.
29.Niculescu, AB 3rd, Kelsoe, JR. Convergent functional genomics: application to bipolar disorder. Ann Med. 2001;33:263–271.
30.Kelsoe, JR, Spence, MA, Loetscher, E, et al.A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc Natl Acad Sci U S A. 2001;98:585–590.
31.Niculescu, AB 3rd, Akiskal, HS. Proposed endophenotypes of dysthymia: evolutionary, clinical and pharmacogenomic considerations. Mol Psychiatry. 2001;6:363–366.
32.Freedman, R, Coon, H, Myles-Worsley, M, et al.Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A. 1997;94:587–592.
33.Myles-Worsley, M, Coon, H, McDowell, J, et al.Linkage of a composite inhibitory phenotype to a chromosome 22q locus in eight Utah families. Am J Med Genet. 1999;88:544–550.
34.Turecki, G, Grof, P, Grof, E, et al.Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. Mol Psychiatry. 2001;6:570–578.